Clinical UpdatesAHA/ACC/HFSA StagingBệnh Thận Do Tiểu Đường
Redefining Risk in Diabetic Kidney Disease: The 2022 AHA/ACC/HFSA Heart Failure Staging and the Efficacy of Sotagliflozin
By MedXY|Mar 20, 2026
This review analyzes the prognostic value of the 2022 Heart Failure staging in patients with diabetes and kidney disease, highlighting the high risk of asymptomatic ‘Pre-HF’ and the consistent therapeutic benefits of sotaglifloz